申请人:Hoffmann-La Roche Inc.
公开号:US20170322225A1
公开(公告)日:2017-11-09
Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.